AC
CLGN icon

Armistice Capital’s CollPlant Biotechnologies CLGN Stock Holding History

Armistice Capital’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.3K Buy
+64,000
New +$64.6K ﹤0.01% 252

Other funds holding CLGN

SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $201M AUM 259.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Armistice Capital's CLGN Position: Q1 2026 in Review

Armistice Capital opened a new position in CollPlant Biotechnologies (CLGN) in Q1 2026: 64,000 shares worth $34.3K. The stake represents ﹤0.01% of the portfolio and ranks #252 among its holdings.

21 funds tracked by Wall St. Rank hold CLGN as of Q1 2026.

  • Armistice Capital held 64,000 shares of CollPlant Biotechnologies worth $34.3K as of Q1 2026.
  • CollPlant Biotechnologies was a new Armistice Capital position in Q1 2026.
  • CollPlant Biotechnologies made up ﹤0.01% of Armistice Capital's portfolio in Q1 2026, its #252 holding.
  • 21 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.